BI_Sifrol Tablets Special Drug Use Surveillance(Survey on the Safety and Efficacy in Parkinson's Disease Patients With Depressive Symptoms)
BI_Sifrol Tablets Special Drug Use Surveillance(Survey on the Safety and Efficacy in Parkinson's Disease Patients With Depressive Symptoms)
The primary objective of this investigation is to conduct a 12-week prospective survey in PD patients with depressive symptoms treated with BI Sifrol Tablets (hereinafter referred to as this drug) in the routine clinical settings to determine the following items related to the safety and efficacy.
i. Adverse drug reaction symptoms, incidence, and severity ii. Motor capacity during the investigation iii. Depressive symptoms during the investigation
Inclusion criteria:
**PD patients with depressive symptoms Patients who have not received pramipexole hydrochloride hydrate preparations within 1 month before survey entrance.
Exclusion criteria:
Fuehuki, Japan
Hirishima, Japan
Inag, Japan
Irima, Japan
Jyoetsu, Japan
Jyoetsu, Japan
Jyoyo, Japan
Kawagchi, Japan
Mihoro, Japan
Miriyama, Japan
Saijyo, Japan
Shinngu, Japan
Tarimizu, Japan
Tokyo Arakawa-ku, Japan
Tokyo Bunkyo-ku, Japan
Tokyo Chuo-ku, Japan
Tokyo Chuo-ku, Japan
Tokyo Daito-ku, Japan
Tokyo Koto-ku, Japan
Tokyo Meguro-ku, Japan
Tokyo Meguro-ku, Japan
Tokyo Minato-ku, Japan
Tokyo Minato-ku, Japan
Tokyo Minato-ku, Japan
Tokyo Nakano-ku, Japan
Tokyo Nerima-ku, Japan
Tokyo Ota-ku, Japan
Tokyo Ota-ku, Japan
Tokyo Setagaya-ku, Japan
Tokyo Setagaya, Japan
Tokyo Shibuya-ku, Japan
Tokyo Shinagawa-ku, Japan
Tokyo Shinjyuku-ku, Japan
Tokyo Shinjyuku-ku, Japan
Tokyo Shinjyuku-ku, Japan
Tokyo Sibuya-ku, Japan
Tokyo Toshima-ku, Japan
Tokyo-Edogawa-ku, Japan
Tokyo-Itabashi-ku, Japan
Yanago, Japan